Epidemiology of acromegaly in Spain;Epidemiología de la acromegalia en España

Endocrinologia y Nutricion

Volumn 60, Issue 8, 2013, Pages 470-474

  Sesmilo, Gemma ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Acromegaly; Cure rates; Epidemiology; Treatment

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; COST OF ILLNESS; DRUG COST; HUMAN; PREOPERATIVE TREATMENT; SHORT SURVEY; SPAIN; TREATMENT FAILURE;

ACROMEGALIA; ACROMEGALY; CURACIÓN; CURE RATES; EPIDEMIOLOGY; ESPIDEMIOLOGÍA; TRATAMIENTO; TREATMENT;

ACROMEGALY; ADENOMA; AGE DISTRIBUTION; COMORBIDITY; CRANIAL IRRADIATION; DOPAMINE AGONISTS; DRUG COSTS; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PITUITARY NEOPLASMS; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SOMATOSTATIN; SPAIN;

EID: 84885383850     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.09.010     Document Type: Short Survey

References (24)

1. Etxabe J., Gaztambide S., Latorre P., Vázquez J.A. Acromegaly: an epidemiological study. J Endocrinol Invest 1993, 16:181-187.
2. Mestrón A., Webb S.M., Astorga R., Benito P., Catalá M., Gaztambide S., et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 2004, 151:439-446.
3. Sesmilo G., Gaztambide S., Venegas E., Picó A., del Pozo C., Blanco C., et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 2012, on behalf of all REA investigators, Epub ahead of print.
4. Luque-Ramírez M., Carreño A., Álvarez Escolá C., del Pozo Picó C., Varela da Costa C., Fajardo Montañana C., et al. The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies. Endocrinol Nutr 2011, 58:478-486. Grupo Español del estudio OASIS.
5. Petersenn S., Buchfelder M., Reincke M., Strasburger C.M., Franz H., Lohmann R., et al. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol 2008, 159:525-532. Participants of the German Acromegaly Register.
6. Fieffe S., Morange I., Petrossians P., Chanson P., Rohmer V., Cortet C., et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 2011, 164:877-884. French Acromegaly Registry.
7. Arosio M., Reimondo G., Malchiodi E., Berchialla P., Borraccino A., de Marinis L., et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 2012, 167:189-198.
8. Bex M., Abs R., T'Sjoen G., Mockel J., Velkeniers B., Muermans K., et al. AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007, 157:399-409.
9. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775.
10. Fernández A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010, 72:377-382.
11. Schneider H.J., Sievers C., Saller B., Wittchen H.U., Stalla G.K. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008, 69:432-435.
12. Cannavò S., Ferraù F., Ragonese M., Curtò L., Torre M.L., Magistri M., et al. Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol 2010, 163:509-513.
13. Shen M., Shou X., Wang Y., Zhang Z., Wu J., Mao Y., et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 2010, 57:1035-1044.
14. Mao Z.G., Zhu Y.H., Tang H.L., Wang D.Y., Zhou J., He D.S., et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 2010, 162:661-666.
15. Carlsen S.M., Lund-Johansen M., Schreiner T., Aanderud S., Johannesen O., Svartberg J., et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008, 93:2984-2990. Preoperative Octreotide Treatment of Acromegaly study group.
16. Losa M., Mortini P., Urbaz L., Ribotto P., Castrignanó T., Giovanelli M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006, 104:899-906.
17. Wang Y.Y., Higham C., Kearney T., Davis J.R., Trainer P., Gnanalingham K.K. Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol (Oxf) 2012, 76:399-406.
18. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152:379-387.
19. Beauregard C., Truong U., Hardy J., Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58:86-91.
20. Swearingen B., Barker 2nd F.G., Katznelson L., Biller B.M., Grinspoon S., Klibanski A., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83:3419-3426.
21. Jane Jr J.A., Starke R.M., Elzoghby M.A., Reames D.L., Payne S.C., Thorner M.O., et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011, 96:2732-2740.
22. Gondim J.A., Almeida J.P., de Albuquerque L.A., Gomes E., Schops M., Ferraz T. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 2010, 29:E7.
23. Sesmilo G., Resmini E., Gaztambide S., Soto A., Pico A., del Pozo C., et al. Características clínicas de los pacientes tratados con Pegvisomant en el registro español de acromegalia (REA). Congreso SEEN 2011, on behalf of all REA participants.
24. Roset M., Merino-Montero S., Luque-Ramírez M., Webb S.M., López-Mondéjar P., Salinas I., et al. Cost of clinical management of acromegaly in Spain. Clin Drug Investig 2012, 32:235-245. Spanish group of the OASIS study.